Haleon plc (NYSE:HLN) Receives Consensus Recommendation of “Hold” from Analysts

Haleon plc (NYSE:HLN) has been assigned a consensus rating of “Hold” from the eight research firms that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $10.95.

Several equities analysts recently commented on the company. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. HSBC reissued a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Finally, Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th.

Haleon Trading Up 0.0 %

Shares of HLN stock opened at $10.05 on Thursday. The firm has a fifty day moving average of $9.90 and a 200-day moving average of $9.88. The stock has a market cap of $45.47 billion, a price-to-earnings ratio of 29.54, a P/E/G ratio of 2.82 and a beta of 0.25. Haleon has a 52-week low of $7.99 and a 52-week high of $10.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, equities research analysts forecast that Haleon will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The firm also recently announced a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This is a positive change from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio (DPR) is 58.97%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HLN. Thrivent Financial for Lutherans raised its stake in shares of Haleon by 69.0% in the third quarter. Thrivent Financial for Lutherans now owns 55,593 shares of the company’s stock worth $588,000 after acquiring an additional 22,701 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Haleon by 41.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 203,583 shares of the company’s stock valued at $2,154,000 after purchasing an additional 59,719 shares in the last quarter. Cerity Partners LLC raised its position in Haleon by 23.4% in the 3rd quarter. Cerity Partners LLC now owns 576,533 shares of the company’s stock worth $6,100,000 after purchasing an additional 109,311 shares during the last quarter. Brown Brothers Harriman & Co. raised its position in Haleon by 80.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 13,653 shares of the company’s stock worth $144,000 after purchasing an additional 6,084 shares during the last quarter. Finally, FMR LLC lifted its holdings in Haleon by 5.8% during the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after buying an additional 5,768,117 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.